NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs

The aim of this work was to develop lead pharmacodynamic hybrids, NO-sartans, possessing the characteristics of a typical AT1-antagonist and of a “slow NO donor”, by adding NO-donor side chains to losartan. These new compounds, 2a and 2b, displayed vasorelaxing effects, due to the release of NO, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medicinal chemistry 2004-11, Vol.47 (23), p.5597-5600
Hauptverfasser:	Breschi, Maria C, Calderone, Vincenzo, Digiacomo, Maria, Martelli, Alma, Martinotti, Enrica, Minutolo, Filippo, Rapposelli, Simona, Balsamo, Aldo
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin II Type 1 Receptor Blockers - chemical synthesis Angiotensin II Type 1 Receptor Blockers - chemistry Angiotensin II Type 1 Receptor Blockers - pharmacology Animals Antihypertensive agents Antihypertensive Agents - chemical synthesis Antihypertensive Agents - pharmacology Biological and medical sciences Blood Pressure - drug effects Cardiovascular system Losartan - analogs & derivatives Losartan - chemical synthesis Losartan - pharmacology Medical sciences Pharmacology. Drug treatments Rats Rats, Inbred SHR Structure-Activity Relationship Vasodilator Agents - chemical synthesis Vasodilator Agents - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!